Education
About Us
Working with TipRanks
Follow Us
Xtant Medical Holdings (XTNT)
:XTNT
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.01Last Year’s EPS
-0.03Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: -16.67%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with strong revenue growth and cost reductions offset by declining gross margins and hardware sales. The company is optimistic about future growth in its Biologics segment and expects overall revenue growth in 2025, although challenges remain in optimizing hardware lines and improving profitability.Company Guidance
In the call, Xtant Medical Holdings, Inc. provided guidance for 2025, projecting total revenue between $126 million and $130 million, representing an 8% to 11% growth. The company emphasized mid-double-digit growth in its Biologics segment, while expecting hardware revenue to remain consistent or slightly decline year over year. Xtant aims to achieve sustainable cash flow by the end of 2025, leveraging cost-saving measures, including a $5 million reduction in operating expenses and a 13% headcount reduction. The company's gross margin for 2024 was 58.2%, with expectations to improve by 4 to 5 points by Q4 2025 due to new product introductions, including four new biologics products. The call highlighted an adjusted EBITDA loss of $2.3 million for 2024, with a net loss of $16.4 million or $0.12 per share. The company also mentioned a $1.5 million licensing fee received in January 2025, with further potential savings from moving distribution to its Belgrade facility.Record Fourth-Quarter Revenue
Achieved record fourth-quarter revenue of $31.5 million, marking a 12% growth quarter-over-quarter and a 28% year-over-year growth.
Positive Adjusted EBITDA
Delivered positive adjusted EBITDA of $438,000 in the fourth quarter, compared to a loss of $695,000 in the same period in 2023.
Biologics Business Growth
Biologics business grew 21% for the year, driven by new products such as OsteoVide Plus and Ambion.
Cost Reduction Achievements
Reduced operating expenses by approximately $5 million and achieved headcount reductions of more than 13%.
2025 Revenue Guidance
Guidance for 2025 projects revenue growth of 8% to 11%, with expectations of mid-double-digit growth in Biologics.
---
XTNT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XTNT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $0.48 | $0.46 | -4.17% |
| Nov 12, 2024 | $0.54 | $0.47 | -12.96% |
| Aug 08, 2024 | $0.65 | $0.65 | 0.00% |
| May 15, 2024 | $0.79 | $0.69 | -12.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Xtant Medical Holdings (XTNT) report earnings?
Xtant Medical Holdings (XTNT) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Xtant Medical Holdings (XTNT) earnings time?
Xtant Medical Holdings (XTNT) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XTNT EPS forecast?
XTNT EPS forecast for the fiscal quarter 2025 (Q1) is -0.01.
---